Alizadeh, 67 patient melatonin ICU RCT: 4% lower mortality [p=0.73], 14% improved recovery [p=0.19], and 27% shorter ventilation [p=0.09] https://c19p.org/alizadeh2
copied to clipboard
High dose melatonin as an adjuvant therapy in intubated patients with COVID-19: A randomized clinical trial
et al., Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.04.012
RCT 67 extremely late stage intubated patients in Iran, showing lower CRP with melatonin treatment, but no significant difference in outcomes.
|
risk of death, 3.8% lower, RR 0.96, p = 0.73, treatment 28 of 33 (84.8%), control 30 of 34 (88.2%), NNT 30.
|
|
risk of no extubation, 13.6% lower, RR 0.86, p = 0.19, treatment 26 of 33 (78.8%), control 31 of 34 (91.2%), NNT 8.1.
|
|
ventilation time, 27.0% lower, relative time 0.73, p = 0.09, treatment 33, control 34.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Alizadeh et al., 5/13/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, Middle East, peer-reviewed, 11 authors, study period June 2020 - September 2020.
Contact:
h-hosami@sina.tums.ac.ir.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.